Nervgen Pharma Corp (TSE:NGEN) has released an update.
NervGen Pharma Corp. has reported a strong year-end with the progression of their NVG-291 Phase 1b/2a clinical trial for spinal cord injury, targeting full enrollment for the chronic cohort by Q2 2024. The company has secured a financial boost with a CA$23 million bought deal financing, ensuring funding through Q3 2025. Additionally, the FDA has awarded Fast Track designation to NVG-291, highlighting its potential to address the critical unmet medical needs of spinal cord injury patients.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
